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Abstract
Background: Although visual acuity and optical coherence tomography (OCT) are most widely used as outcomes
in treatment of neovascular age-related Macular Degeneration (nAMD), patient reported outcome measures are
increasingly recognized. National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) was developed to capture
the perceived visual function. Yet, evidence of psychometric performance in the target population is required. The
aim of this study was to examine the psychometric properties of NEI-VFQ 25 in a Norwegian cohort of newly
diagnosed nAMD patients followed with a Treat and Extend (T/E) protocol.
Methods: Patients receiving intravitreal anti–vascular endothelial growth factor (anti-VEGF) injection treatment
according to a T/E protocol completed a Norwegian translation of NEI-VFQ 25, EuroQoL Health Questionnaire (EQ-5D),
and Patient acceptable symptom state (PASS 5) at baseline, 3, 6 and 12months. In addition, a control population
completed the same questionnaires. Visual acuity was assessed with LogMar for best/treated eye. Validity testing
comprised face validity by a 0–10 numeric rating scale about relevance of NEI-VFQ 25 as well as regression analyses
and correlations between NEI-VFQ 25 and other relevant variables. Reliability was examined with Intraclass Correlation
Coefficient (ICC) and Cronbach’s alpha for internal consistency were performed. Responsiveness, discriminatory power
and predictive value were also explored.
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Results: Number of respondents at baseline, after 3, 6 and 12months was 197, 186, 176 and 168, respectively. The
control population comprised 26 individuals. Face validity of NEI-VFQ 25 had a mean (SD) of 7.8 (1.7) (n = 84). NEI-VFQ
was significantly correlated to visual acuity and PASS 5 as well as EQ-5D at baseline. Reliability (ICC) of the overall and
sub scores for the patients/controls ranged from 0.49–0.97/0.59–0.97. Cronbach’s alpha was 0.61–0.85. Discriminatory
power was confirmed by significant differences of the overall score between controls and patients (P < 0.001). NEI-VFQ
25 indicates responsiveness showing overall score improved significantly (P≤ 0.001) from baseline to 3months. NEI-
VFQ 25, general health and visual acuity at baseline were the strongest predictors for how patients reported vision after
6 months follow-up.
Conclusion: NEI-VFQ 25 showed acceptable psychometric performance, which supports that the Norwegian version
can be used to monitor patients treated for nAMD.
Keywords: Age-related macular degeneration, Intravitreal injections, Anti-VEGF, Patient reported outcome measures,
NEI-VFQ 25, Validation, Questionnaire
Introduction
Visual acuity levels and retinal thickness measured with op-
tical coherence tomography (OCT) are often used as pri-
mary outcome measures in evaluating treatment for
neovascular age-related Macular Degeneration (nAMD) [1,
2]. However, it is increasingly important to reflect the pa-
tient’s perspective concerning not only the treatment effect,
but also the visual function in everyday life [3–6]. The Food
and Drug Administration (FDA) and The European Medi-
cines Agency (EMA) recommend researchers to show
benefit in patient reported outcome measures (PROMs) for
approval of new drugs or treatments [7–9]. Generic
PROMs are useful in comparisons across diseases and pop-
ulations, while disease-specific PROMs are usually more
sensitive to disease-related characteristics. The two kinds of
PROMs are recommended to be used in conjunction [10].
NEI-VFQ 25 is a vision specific PROM, reporting on
visual function in everyday life [4, 11, 12]. NEI-VFQ 25
has been validated across ocular diseases such as glau-
coma, cataract and AMD in different countries across
the world including Sweden, Greece, Denmark, Serbia,
Turkey, Germany, Italy, China, Thailand, Japan, and
Brazil [13–18]. NEI-VFQ 25 has also been shown to cor-
relate with visual acuity in patients treated with repeti-
tive intravitreal anti-VEGF injections for nAMD [19, 20]
and is considered as a tool which is sensitive to change
in visual acuity [5, 19, 21]. Psychometric testing of a
questionnaire is always required in target population and
a new cultural setting [22, 23]. The aim of this study was
to test psychometric performance of the Norwegian ver-
sion of NEI-VFQ 25 in a longitudinal cohort study of
newly diagnosed nAMD patients treated with an individ-
ualized Treat and Extend (T/E) protocol.
Methods
Patients and controls
Newly diagnosed nAMD patients with indication for in-
travitreal anti-VEGF therapy, as well as controls without
known eye disease above 60 years of age were included
in the study. The standard anti-VEGF protocol used was
an individualized T/E regimen with bevacizumab as
first-line of treatment as previously described [24–26].
The controls were relatives following patients to their
clinical examination at the hospital. For both groups, we
included Scandinavian speaking persons without cogni-
tive impairment. Recruitment procedure was performed
by researchers who were not involved in diagnosis or
treatment.
Data collection
The participants who met the inclusion criteria com-
pleted the baseline questionnaire at the outpatient clinic.
Patients were interviewed at baseline, as well as 3, 6 and
12months after the initiation of treatment. A subset of
30 patients to examine test-retest reliability was inter-
viewed one week after 6 months. The controls responded
to the questionnaire initially at the outpatient clinic and
then one week after for test-retest. All follow-up inter-
views were performed by the telephone.
NEI-VFQ 25
Both patients and controls responded to NEI-VFQ 25,
which measures patient reported visual function. NEI-
VFQ 25 contains 25 questions on visual function in daily
life. This 25-item questionnaire is a shorter version of an
original questionnaire containing 51 questions. There
are also other versions of NEI-VFQ [27].
NEI-VFQ 25 has a total score ranging from 0 to 100
(where 100 reflects best health). It contains 12 subcat-
egories: general health, general vision, ocular pain, near
vision activities, distance activities, social functioning,
mental health, role difficulties, dependency, driving,
color vision and peripheral vision. The interviewer-ad-
ministered format of NEI-VFQ 25 was used. The inter-
viewer-administrated version involves interviewer
reading the questions to the patients and writing down
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the patient’s answers. This applied version of NEI-VFQ 25
was translated to Norwegian by Mapi Trust (Mapi Trust
27 rue de la Villette, 69003 Lyon, France), which also gave
permission to use the Norwegian version. Mapi Trust did
a linguistic validation process which was officially ap-
proved by the developer of the original instrument.
Other instruments
To be able to compare NEI-VFQ 25 with other relevant
instruments, patients responded to EQ-5D-3 L EuroQoL
Health Questionnaire 3 Level version [28] to measure
utility. EQ-5D-3 L contains 5 questions on mobility, self-
care, usual activities, pain/discomfort and anxiety/de-
pression with 3 graded response options. We also used
PASS 5 (Patient Acceptable Symptom Status) [29],
which can be used as a measure for the level of accept-
ability of symptom status on a Likert scale 1–5 (where 1
is best, and 3 is acceptable) in this case visual symptom
state.
Visual acuity was measured as the Logarithm of the
minimal angle of resolution (LogMar) for both eyes from
routine measurements at consultations in the outpatient
clinic. Demographic data were collected to describe the
age, gender, employment and marital status of the study
population. All data collection for PROMs was per-
formed as interviews due to the patient’s poor vision and
high age.
Analyses
Face validity was tested in a subgroup of 84 patients
who graded the relevance of the questionnaire on a nu-
meric rating scale from 0 to 10, where 10 indicated high
relevance.
Unadjusted and adjusted regression analyses were used
to identify associations between NEI-VFQ 25 overall
score and EQ-5D, PASS 5, demographic variables, as
well as clinical variables like acuity of best and treated
eye in LogMar. Further, we did correlation analyses
which also included sub scores of NEI-VFQ 25. Q-Q
plots and median versus mean values indicate that the
data were mainly not normally distributed. We therefore
chose to use Spearman correlation analyses.
Test-retest reliability was examined one week apart at
6 months follow-up for patients and one week after base-
line for the controls with Intraclass Correlation Coeffi-
cient (ICC) 2 way-mix method. Reliability was examined
both for the overall and the sub-scores which were based
on more than one item. ICC was evaluated to be either
poor (< 0.5), moderate (0.5–0.75), good (0.75–0.9) or ex-
cellent (> 0.9) according to criteria described by Koo and
Li [30]. Internal consistency was tested using Cronbach’s
alpha on the overall and sub scores of NEI-VFQ 25.
Paired T-tests (baseline vs 3 months) were performed
to examine responsiveness of NEI-VFQ 25. The same
tests were performed on LogMar treated and best eye.
Two-sample T-tests were used for the testing the dis-
criminatory power of NEI-VFQ 25 between the patient
and control groups.
Finally, the predictive value of baseline NEI-VFQ 25
was examined by a multivariable regression analysis with
the overall score at 6 months as the dependent variable.
The multivariable regression analysis included relevant
variables as EQ-5D, PASS 5, demographic variables, and
clinical variables like acuity of best and treated eye in
LogMar.
Results
Newly diagnosed nAMD patients (71% females, mean
(SD) age 83.4 (7.6) years) responded to NEI-VFQ 25 at
baseline (n = 197), 3 (n = 186), 6 (n = 176) and 12 (n =
168) months after initiating anti-VEGF treatment. The
mean number of injections during 3 months was 2.35
(0.85) and 4.31 (1.61) during the 6months follow-up.
The majority of patients were treated with bevacizumab
(97% at baseline). Significant improvement at 3, 6 and
12months was found for LogMar in best (P < 0.05) and
treated eye (P < 0.001). In addition, 26 controls (48% fe-
males, mean (SD) age 70.2 (7.7) years) were included in
the study.
The mean overall score of NEI-VFQ 25 at baseline
was 79.5 and 91.3 out of 100 in patients and controls, re-
spectively. The sub-scores in patients varied from 46.8
(general health) to 94.4 (peripheral and color vision).
Controls had a variation in sub-scores from 65.4 (general
health) to 99.0 (color vision). Visual acuity in patients
was 20/31 for best and 20/78 for treated eye (LogMar
0.19/0.59). Self-reported level of acceptable (vision)
symptom status (PASS 5) was reported acceptable or be-
yond (54.3%) in the patient group, while 92% in the con-
trol group reported acceptable level or beyond (Table 1).
Validity of NEI-VFQ 25
Face validity of NEI-VFQ 25 showed a mean (SD) of 7.8
(1.7) for the numeric rating scale.
NEI-VFQ 25 overall score was not associated with
demographic data, but significant associations were
found between visual acuity at both best (P < 0.001) and
treated eye (P = 0.01) at baseline as well as with PASS 5
and EQ-5D, both in unadjusted and adjusted multiple
regression analyses (Table 2).
The results from cross-sectional multiple regression
analyses at 3-, 6- and 12-month follow-up were similar
with regard to associations between NEI-VFQ 25 and
demographic and disease related variables. However,
NEI-VFQ 25 overall score was not significantly associ-
ated to EQ-D5 at 6 and 12months and to LogMar
treated eye at 12 months (data not shown).
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Baseline sub-scores of NEI-VFQ 25 correlated sig-
nificantly with visual acuity in both best and treated
eye and with PASS 5, except for general health, ocu-
lar pain, and peripheral vision. General vision was not
correlated to LogMar treated eye. EQ-5D was strongly
correlated to general health sub-score but was not
significantly correlated to color nor peripheral vision
(more details in Table 3).
Reliability and internal consistency
ICC values were 0.91 for NEI-VFQ 25 overall score in the
patient group and 0.96 in the control group. ICC values for
all sub scores of NEI-VFQ 25 in the patient group were ran-
ging from 0.49 for role difficulties to 0.97 for driving
(Table 4). In the control group all sub scores except one
showed an ICC value of 0.59 or higher (Table 4). There
were 9 of 12 sub-categories with a > 0.7 ICC value in the
Table 1 Baseline descriptive characteristics
Patients (N = 197) Controls (N = 26)




Visual Acuity of best eye (LogMar) 0.19 (0.25) NA
Fractional 20/31
Visual Acuity of treated eye (LogMar) 0.59 (0.51) NA
Fractional 20/78
NEI-VFQ 25 overall score of 100 79.5 (14.5) 91.3 (7.7)
NEI-VFQ 25: sub scores:
General Health 46.8 (23.1) 65.4 (25.6)
General vision 57.1 (17.7) 83.1 (12.3)
Ocular Pain 88.4 (19.5) 85.0 (18.7)
Near activities 74.1 (22.4) 88.0 (13.0)
Distance activities 75.7 (24.6) 91.7 (9.0)
Social Function 85.1 (21.6) 98.0 (6.0)
Mental health 77.2 (19.0) 91.0 (10.4)
Role difficulties 69.3 (30.0) 90.0 (20.1)
Dependency 89.7 (16.5) 98.7 (5.2)
Driving 61.9 (38.0) 83.7 (20.0)
Color vision 94.4 (14.1) 99.0 (5.0)
Peripheral vision 94.4 (14.5) 95.2 (10.4)
EQ-5D index 0.74 (0.28)a 0.85 (0.18)
PASS 5- Visual symptom status:
Acceptable and over 54.3% 92.0%
Below acceptable 45.6% 8.0%
NA = Not available in this group. Available in N = 132
Table 2 Associations between demographic and disease related variables with NEI-VFQ 25 at baseline
Variable Unadjusted effect 95% CI P-value Adjusted effect* 95% CI P-value
Age − 0.106 (− 0.374, 0.161) 0.44 0.15 (−0.08, 0.38) 0.21
Gender 3,056 (−1.410, 7.522) 0.18 1.84 (−1.89, 5.58) 0.33
Marital status −0.546 (−2.003, 0.911) 0.46 −0.11 (−1.17, 1.39) 0.86
LogMar best eye −26.367 (−33.321, −19.413) < 0.001 − 20.25 (− 26.76,-13.75) < 0.001
LogMar treated eye − 7.258 (− 11.151, − 3.365) < 0.001 − 4.25 (− 7.46,-1.05) 0.01
EQ-5D score 19.439 (12.569, 26.309) < 0.001 17.83 (11.99, 23.66) < 0.001
PASS 5 −7.196 (−9.545, −4.846) < 0.001 −5.11 (− 7.15, − 3.07) < 0.001
*Adjusted for all variables in multiple regression analyses. Bold values = P < 0.001 and P < 0.05
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patient group (Table 4). Concerning the internal
consistency, the overall scores in Cronbach’s alpha was 0.85
for overall score and 0.61–0.78 in sub-scores [31].
Responsiveness, discriminatory power and predictive
value
NEI-VFQ 25 overall score showed a significant improve-
ment (P ≤0.001, CI:-3.55,-1.33 ) from baseline to 3
months (Table 5), that was also seen at 6 months (P =
0.001, CI:-3.88,-1.04), and at 12 months (P = 0.033, CI: −
3.33, − 0.14). Longitudinal changes were also statistically
significant for PASS but not for EQ-5D (data not shown
for 6 and 12months).
NEI-VFQ 25 overall score was significantly different in
nAMD patients and controls (P < 0.001 and CI:-17.639,-
5.975), supporting discriminatory power. All sub scores
also showed significant difference between the two
groups, except for peripheral vision, color–vision and
ocular pain (data not shown).
Baseline predictors of NEI-VFQ 25 overall score
after 6 months were explored in a multivariable re-
gression analysis. The following variables were signifi-
cant; NEI-VFQ 25 (P = 0.001, CI = 0.53, 0.84), LogMar
best eye (P = 0.02, CI = -19.05,-1.74) and EQ-5D score
(P = 0.03, CI = 0.68, 15.27). LogMar treated eye was
borderline significant (P = 0.05, CI = -8.99, 0.06)
(Table 6). These results show that baseline NEI-VFQ
25 overall score, general health and visual acuity are
the strongest predictors for how patients report vision
after 6 months follow up.
Table 3 Baseline correlations (Spearman) between visual acuity in LogMar treated- and best eye with NEI VFQ-25 Scores
VFQ-25 Subscale/ Overall Score LogMar best eye LogMar treated eye EQ-5D PASS
General health − 0.10 0.33 0.48** −0.25
General vision −0.35** −0.14 0.25** −0.57**
Ocular pain −0.02 0.08 0.18* −0.05
Color vision −0.23 ** −0.22** 0.05 −0.09
Near activities −0.41** −0.14* 0.26** −0.40**
Distance activities −0.31** −0.15* 0.32** −0.25**
Social function −0.25** −0.11 0.27** −0.29**
Mental health −0.32** −0.20** 0.36** −0.32**
Role difficulties −0.30** −0.16* 0.31** −0.38**
Dependency −0.35** −0.20** 0.31** −0.26**
Peripheral vision −0.09 −0.15* 0.09 −0.14*
Driving −0.37** −0.29** 0.13 −0.24*
Total score −0.40** −0.21** 0.35** −0.45**
Correlation coefficient *P < 0.05 **P < 0.001
Table 4 Internal consistency at baseline and test-retest reliability of NEI-VFQ 25 in patient and control group
NEI-VFQ 25 Number of items Cronbach’s Alpha in patients (N = 175) ICC in patients (N = 31) ICC in controls (N = 21)
General Health 1 NA 0.64 0.78
General vision 1 NA 0.51 0.72
Ocular Pain 2 0.64 0.91 0.89
Near activities 3 0.74 0.87 0.65
Distance activities 3 0.77 0.90 0.68
Social Function 2 0.66 0.93 0.83
Mental health 4 0.69 0.80 0.65
Role difficulties 2 0.78 0.49 0.92
Dependency 3 0.76 0.75 0.59
Driving 2 0.61 0.97 0.97
Color vision 1 NA 0.89 −0.11
Peripheral vision 1 NA 0.96 0.60
25-item composite 25 0.85 0.91 0.96
NA = Not Applicable
ICC = Intraclass Correlation Coefficient
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Discussion
NEI-VFQ 25 was originally designed and validated for
the American language and culture. The aim of this
study was to test the psychometric properties of NEI-
VFQ 25 in a Norwegian population of nAMD patients
treated with intravitreal injections according to a T/E
protocol. The longitudinal data in this study provided an
opportunity to look at a broader set of analyses, like reli-
ability, responsiveness and predictive value.
The added value of PROMs to clinical outcomes gives
a better understanding of how treatment and disease is
experienced by the patients [32]. Including EQ-5D for
the validation of NEI-VFQ 25 was chosen because it is a
valid, generic measure with the advantage of its brevity
[33–35].
Including controls enabled us to test discriminatory
power. However, a limitation to this is the relatively
small sample size in the control group. We were unable
to include sufficiently matched controls as to demo-
graphic characteristics since the mean age difference was
13 years between the patients and the controls and the
sex ratio also differed. However, such differences are also
seen in similar relevant studies [17, 36].
Using interviewer administered version of NEI-VFQ 25
made it possible to explain questions that were unclear for
the patients who generally had high age and poor vision.
However, the interviewer administered format can contain
a risk of bias. Previous studies have shown that patients
report better scores of health related quality of life with
interviewer administrated than self-administrated ver-
sions. Whether health-related quality-of-life measure-
ments are affected by the format of administration or not,
is a subject of discussion [31, 37, 38].
Some items in NEI-VFQ 25 needed more explan-
ation, probably mostly due to an aging population
with various degree of hearing impairment. With the
combination of high age and reduced central vision,
we thus recommend the interviewer-administered for-
mat of NEI-VFQ 25 as preferable for nAMD patients.
Our study population of Norwegian nAMD patients
had higher sub-scores and overall score of NEI-VFQ
25 at baseline (79.5), compared to the two large stud-
ies of nAMD populations MARINA (69.3) and AN-
CHOR (69.9) [19]. The only lower sub-score in our
study compared to MARINA and ANCHOR was gen-
eral health. The high overall score at baseline may be
a reflection of the efficiency in the early diagnosis of
nAMD in the present patient population of the Nor-
wegian capital and surrounding areas. One explan-
ation for lower general health sub-score of this
nAMD Norwegian population might be due to the
patient’s high age (83.4 years) compared to MARINA
(77.1) and ANCHOR studies (77.0 years).
High face validity in our study suggests that NEI-VFQ
25 can be considered as relevant by the patients. This
can be due to the patient-derived way NEI-VFQ was ori-
ginally developed by including patients to identify prob-
lems in different visual diseases like AMD [39].
Table 5 Improvement in NEI-VFQ 25 and other measures in nAMD patients after 3 months of intravitreal anti-VEGF treatment
Variables Baseline 3 months P-value of baseline-3 months
NEI-VFQ 25 score 79.53 (14.52) 82.20 (13.68) < 0.001
EQ-5D score 0.74 (0.28) 0.70 (0.32) 0.64
PASS 5 3.29 (0.80) 2.82 (0.80) < 0.001
LogMar best eye 0.19 (0.03) 0.15 (0.22) 0.015
LogMar treated eye 0.59 (0.49) 0.44 (0.42) < 0.001
Bold values = P < 0.001 P < 0.05
Table 6 Baseline predictors of NEI-VFQ 25 overall score after 6 months explored in multivariable regression analyses
Variable Unadjusted effect 95% CI P-value Adjusted effect* 95% CI P-value
Age −0.24 −0.52,0.05 0.11 0.09 −0.18,0.36 0.52
Gender 0.41 −0.34,5.16 0.86 −2.54 −7.19,2.11 0.28
Marital status −1.05 −2.59,0.48 0.24 −0.88 −2.34,0.59 0.24
LogMar best eye −25.58 −33.02, −18.14 < 0.001 −10.40 −19.04,-1.74 0.02
LogMar treated eye −6.87 −11.64,-2.10 0.005 −4.47 −8.99,0.06 0.05
EQ-5D score 18.01 8.41,27.61 < 0.001 7.98 0.68,15.27 0.03
NEI-VFQ 25 baseline 0.80 0.71,0.90 < 0.001 0.69 0.53,0.84 < 0.001
Treatment intensity 1.53 −3.07,0.01 0.05 −0.47 −2.29,1.35 0.61
PASS 5 −4.83 −7.46,- 2.21 < 0.001 0.15 −2.24,2.55 0.89
*Adjusted for all variables in multiple regression analyses. Bold values = P < 0.001 and P < 0.05
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Our results show that all correlations are below 0.5,
hence 0.52 = 25% or less of the variations are explained
by the visual acuity for treated eye and best eye, EQ-5D
and PASS 5 (in Table 3) [40]. These moderate correla-
tions were similar to those found by two other studies
performed on nAMD population [20, 27]. NEI-VFQ 25
validity seems acceptable, since it is significantly corre-
lated to most relevant variables. However, a possible ex-
planation for the generic EQ-5D not significantly being
associated to the disease specific NEI-VFQ 25 at 6 and
12months may be that disease specific measures are
more sensitive to change, and that general health will
usually not change as quick as vision in nAMD patients.
Concerning the associations between sub-scores and
objective visual acuity, our results are similar to other
studies showing strongest correlations between the sub-
scores and best eye, confirming that patients who have a
lower best corrected visual acuity report lower visual
function. However, preserving vision on treated eye indi-
cates a significant impact on visual function [41–43].
Sub-categories as peripheral vision, ocular pain and gen-
eral health were not significantly correlated with visual
acuity nor with PASS 5, which may indicate that these
sub-scores are not the strongest associates for patients
with nAMD which is coherent with other studies on
same population [5, 41]. Orr et al., who were examining
correlations between sub-scores and visual acuity in best
and worst eye, found similar results (except for periph-
eral vision) [20]. Results were also similar in the same
population with the longer version of NEI-VFQ 39 [42].
Testing reproducibility with test-retest at 6 months
after initiation of treatment was chosen since clinical ex-
perience has shown that this period is more stable for
the patients than earlier in treatment. A possible limita-
tion of this test is the risk of patients remembering the
questions of NEI-VFQ 25, since the set time limit be-
tween the test and retest was only one week. However,
shorter period like this for a relatively large sample size,
25 questions and an older patient population who easily
forget, are likely to give memory minor influences on
the retest.
High reliability was demonstrated in test-retest ana-
lyses for patient group, showing the majority (9 of 12) of
the sub-scores with a good or excellent ICC values and
3 out of 12 being moderate. The overall score had excel-
lent reliability (0.91) [30]. Other studies testing NEI-
VFQ 25 on different ocular diseases including nAMD
have shown ICC values from 0.6–0.7 and higher (except
for general vision and role difficulties) [13, 16, 17, 44].
Lower ICC values have been shown in other studies on
general vision and general health [45, 46]. Some values
in test-retest analyses for the healthy controls were re-
ported to be poor in our study, such as color vision,
which could be due smaller sample and the potential
ceiling effect [47]. Regarding internal consistency, Soren-
sen et al., reported a low value of 0.4 on ocular pain and
0.5 on driving [17]. Other studies have reported similar
results in nAMD populations, which are coherent to our
results [20, 42].
We found a significant difference between the patients
and controls which supports discriminatory power, both
for the overall score and most sub scores – excluding
color- and peripheral vision and ocular pain, which is in
agreement with the results from the Danish study [17].
Another study performed on patients with nAMD showed
significantly lower scores than control group for all sub-
scores except for ocular pain [36]. The discriminatory
power of NEI-VFQ 25 has also been shown in other stud-
ies of ocular diseases including nAMD [15, 16, 45, 46].
Our results support that the Norwegian version of NEI-
VFQ 25 is responsive, which is coherent with the results
from a large study on a similar population [19]. These re-
sults are coherent to statistically significant improvement
in objectively observed visual acuity by LogMar both on
treated and best eye. Responsiveness has also been tested
in other studies exploring psychometric properties of
NEI-VFQ 25 on different ocular diseases including nAMD
and has overall shown similar results [45, 48]. Miskala et
al. found that peripheral and color vision and ocular pain
were not significantly affected by poor vision and less af-
fected in nAMD [21], which is similar to our results.
Other studies have also found corresponding correlations
between sub-scores and visual acuity, which are associated
with central vision [15, 44, 48].
Rasch analyses and Item Response Theory are rela-
tively new analyses used to develop, evaluate and im-
prove patient reported outcomes. They might have been
relevant in current study, to both evaluate and poten-
tially suggest improvement in items of NEI-VFQ 25 as
an previous study has shown in the same population
[49]. However, the aim in the present study was not such
an extensive evaluation, but rather to validate the ori-
ginal measure in a Norwegian population with nAMD.
We believe that this would be a valuable approach in fu-
ture evaluations of NEI-VFQ-25 in this population.
Conclusion
The Norwegian version of NEI-VFQ 25 showed satisfac-
tory psychometric properties, including validity, reliabil-
ity, responsiveness, discriminatory power and predictive
value. The added value of monitoring patient’s subjective
visual function in clinical settings, is a better under-
standing of how to target the individualized needs of the
patients with nAMD. Acknowledging the requirement
for psychometric performance of PROM that is shown
in this study, may support an extended use of NEI-VFQ
25 in patients with nAMD in scientific studies in
Norway.
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